Niki BioSolutions, Inc. filed a Current Report on Form 8-K dated September 14, 2026, to disclose a corporate presentation. The document outlines the completion of a business combination with DiamiR Biosciences Corp. and Aptorum Group Limited.
The all-stock merger was finalized on July 20, 2026, following shareholder approval. Under the terms of the agreement, DiamiR shareholders own approximately 70% of the combined company, while Aptorum shareholders hold about 30%.
The presentation highlights strategic synergies between the entities, focusing on diagnostics and therapeutics. It emphasizes a leadership team with commercial expertise and a robust intellectual property portfolio.
Niki BioSolutions, through its DiamiR subsidiary, focuses on developing molecular diagnostics and pharmaceutical services. The subsidiary operates a CLIA-licensed, CAP-accredited, and New York State-licensed clinical laboratory in New Haven, Connecticut. The company specializes in non-invasive blood-based diagnostic solutions for Alzheimer's disease and brain health.
The presentation details a pipeline of diagnostic products, including an APOE genotyping test approved by New York State and a CogniMIR test for Alzheimer's risk. The company is also pursuing proof-of-concept studies for tests related to Rett syndrome, glioblastoma, and Long-COVID.
Management identifies opportunities in the Alzheimer's disease testing market, which is described as large, underserved, and fragmented. The presentation notes that two disease-modifying drugs were approved in the last two years and discusses the role of blood biomarkers in identifying pathology pre-symptomatically.
Niki BioSolutions aims to provide scalable blood tests for early intervention and testing solutions for pharmaceutical trial recruitment. The company also plans to offer pharma services to support therapeutic development efforts.
